• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Review: LABAs okay only with steroids

Article

The worry about safety with long-acting beta agonists (LABAs) should not be a problem, provided the LABAs are used with a corticosteroid...

The worry about safety with long-acting beta agonists (LABAs) should not be a problem, provided the LABAs are used with a corticosteroid.

The UK's Medicines and Healthcare products Regulatory Agency (MRHA) reviewed safety data from the asthma/COPD treatments after the postmarketing "SMART" study. The study found a statistically significant increase in deaths from respiratory- and asthma-related reasons for users of LABAs.

The review found that there has been a marked decrease in the number of hospitalizations for asthma, as well as the number of asthma-related deaths. More postmarekting studies are being done on LABAs in 2008.

For the time being, LABAs are considered safe when used in combination with an inhaled steroid. Many products already combine the two medications.

Related Videos
Importance of maternal influenza vaccination recommendations
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Samantha Olson, MPH
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
Steven Selbst, MD
© 2024 MJH Life Sciences

All rights reserved.